Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Cancer Antibodies: Competitive Positioning for Success.


DUBLIN Dublin, city, Republic of Ireland
Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River.
, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/5236e3/cancer_antibodies) has announced the addition of the "Cancer Antibodies: Competitive Positioning for Success" report to their offering.

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. The author has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs A blockbuster drug is a drug generating more than $1 billion of revenue for its owner each year. The search for blockbusters has been the foundation of the R&D strategy adopted by big pharmaceutical companies, but this looks set to change. . This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely con·verse 1  
intr.v. con·versed, con·vers·ing, con·vers·es
1. To engage in a spoken exchange of thoughts, ideas, or feelings; talk. See Synonyms at speak.

2.
 it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. The author has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.

In the report, the author reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to according to
prep.
1. As stated or indicated by; on the authority of: according to historians.

2. In keeping with: according to instructions.

3.
 targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions Protein-protein interactions refer to the association of protein molecules and the study of these associations from the perspective of biochemistry, signal transduction and networks.

The interactions between proteins are important for many biological functions.
 between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.

Why You Should Own Your Own Copy of this Report:

* 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet Internet

Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the
 

* A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer

* 145 unique, in-depth, drug target validating val·i·date  
tr.v. val·i·dat·ed, val·i·dat·ing, val·i·dates
1. To declare or make legally valid.

2. To mark with an indication of official sanction.

3.
 profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project The Cancer Genome Project, based at the Wellcome Trust Sanger Institute, aims to identify sequence variants/mutations critical in the development of human cancers.

The Cancer Genome Project combines knowledge of the human genome sequence with high throughput mutation
 etc.

* A unique drug target combination breakdown of cancer antibodies into tumor tumor: see neoplasm.  type and developmental stage

* Unique drug-protein target interactome - and protein-protein of drug targets interactome analysis

* Pathway profiling of cancer antibody drug targets

* Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development

* Who are working on sequels to blockbuster drugs?

* Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.

on·col·o·gy
n.
 drug targets and the selection/validation of targeting strategies.

For more information visit http://www.researchandmarkets.com/research/5236e3/cancer_antibodies
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 11, 2008
Words:539
Previous Article:Research and Markets: Compania Espanola de Petroleos, S.A. (Cepsa) Strategic Analysis Profile Is Available Now.
Next Article:Eva Kaijser Appointed Senior Vice President, Strategy and Business Development at Boliden.
Topics:



Related Articles
Altarex awarded key foreign patent for Ait cancer technology.
Urogenesys and Genentech sign agreement for prostate cancer antibody therapy.
Millennium and BZL Biologics agree to develop antibodies against prostate cancer.
Altarex licenses United States issued patents for autoimmune disease therapy.
Genetastix strengthens antibody library intellectual property.
Peregrine announces patent grant for angiogenesis therapy.
Peregrine extends its platform of anti-cancer technologies.
CFD Therapeutics formed to advance monoclonal antibodies for cancer.
CFD Therapeutics formed to advance monoclonal antibodies for cancer.
Lpath granted patent protection for anti-cancer anti-S1P antibody.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles